PetMed Express, Inc. (NASDAQ:PETS) Receives Consensus Recommendation of “Hold” From Analysts

Pet Med Express, Inc. (NASDAQ: PETSget rating) has received an average “Hold” recommendation from the six brokerage houses that currently cover the company, reports. One research analyst rated the stock a sell rating, three assigned a hold rating and one assigned a buy rating to the company. The average 1-year target price among brokerage firms that have issued a report on the stock in the last year is $27.00.

PETS has been the subject of several analyst reports. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $32.00 price target for the stock in a research note on Thursday, January 20. Morgan Stanley lowered its price target on PetMed Express from $25.00 to $21.00 and placed an “underweight” rating on the stock in a research note on Tuesday, January 25. started coverage on PetMed Express in a research note on Thursday, March 31. They issued a “hold” rating on the stock. Finally, Zacks Investment Research updated PetMed Express from a “strong sell” rating to a “hold” rating in a research note on Wednesday, March 30.

Actions of pet actions opened at $24.15 on Monday. The company’s 50-day moving average is $26.27 and its 200-day moving average is $26.61. PetMed Express has a twelve month minimum of $21.64 and a twelve month maximum of $46.67. The company has a market capitalization of $506.64 million, a P/E ratio of 22.36, and a beta of 0.45.

Pet Med Express (NASDAQ: PETSget rating) last announced its earnings results on Monday, January 24. The company reported earnings per share of $0.21 for the quarter, missing the consensus estimate of $0.30 per ($0.09). PetMed Express had a net margin of 7.83% and a return on capital of 16.00%. The company had revenue of $60.72 million during the quarter, compared to analyst expectations of $61.90 million. During the same quarter last year, the company posted earnings per share of $0.38. Research analysts expect PetMed Express to post 1.06 EPS for the current year.

See also  Bobby and more pets up for adoption at Phoenix-area shelters

Institutional investors and hedge funds have recently bought and sold shares of the company. Fisher Asset Management LLC increased its position in PetMed Express by 98.9% during the fourth quarter. Fisher Asset Management LLC now owns 87,935 shares of the company worth $2,221,000 after purchasing an additional 43,717 shares last quarter. WBI Investments Inc. purchased a new stake in PetMed Express during the fourth quarter for $513,000. Allianz Asset Management GmbH increased its position in PetMed Express by 38.7% during the third quarter. Allianz Asset Management GmbH now owns 380,630 shares of the company worth $10,228,000 after buying an additional 106,275 shares in the last quarter. The Maryland State Retirement and Pension System purchased a new stake in PetMed Express during the third quarter for $219,000. Finally, Atom Investors LP strengthened its position in PetMed Express by 255.9% during the third quarter. Atom Investors LP now owns 23,281 shares of the company worth $626,000 after purchasing an additional 16,740 shares in the last quarter. Institutional investors own 80.50% of the company’s shares.

PetMed Express Company Profile (get rating)

PetMed Express, Inc, along with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications and other health products for dogs, cats and horses. Offers over-the-counter medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, candy, nutritional supplements, hygiene products and supplies; and prescription drugs, including heartworm preventives, flea and tick preventives, arthritis, dermatitis, thyroid, diabetes, pain relievers, heart/blood pressure, and other specialty medications, as well as substitutes generic.

See also  Best TSA Approved Pet Carrier | WJHL

Featured articles

Receive news and ratings from PetMed Express daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for PetMed Express and related companies with’s FREE daily e-newsletter.